Status:
COMPLETED
Moxonidine for Prevention of Post-ablation AFib Recurrences
Lead Sponsor:
Spyridon Deftereos
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
25-80 years
Phase:
PHASE4
Brief Summary
Hypothesis: Modulation of central nervous sympathetic activation by administration of moxonidine, a centrally acting medication which decreases the sympathetic nervous system activity, can lead to a d...
Eligibility Criteria
Inclusion
- Hypertensive patients with paroxysmal atrial fibrillation.
- At least two documented episodes within the last 12 months (either self-terminating within 7 days or cardioverted, medically or electrically, in less than 48 hours).
- At least one episode should have been documented under treatment with a class Ic or III antiarrhythmic drug.
Exclusion
- age \<25 or \>80 years
- presence of atrial thrombus
- left atrial volume index \>55 ml/m2
- hypersensitivity to moxonidine
- sick sinus syndrome or sino-atrial block
- 2nd or 3rd degree atrioventricular block
- bradycardia (below 50 beats/minute at rest)
- estimated glomerular filtration rate \<40 ml/min/1.73 m2
- history of angioneurotic oedema
- heart failure symptoms OR impaired left ventricular function (EF \<40%), even if asymptomatic
- stable or unstable angina pectoris
- intermittent claudication or known peripheral artery disease
- Parkinson's disease
- epileptic disorders
- glaucoma
- history of depression
- pregnancy or lactation
- inability or unwillingness to adhere to standard treatment or to provide consent.
Key Trial Info
Start Date :
August 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2014
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01791699
Start Date
August 1 2012
End Date
April 1 2014
Last Update
May 6 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Evangelismos General Hospital
Athens, Greece, 10676
2
Athens General Hospital "G. Gennimatas"
Athens, Greece, 11527
3
Red Cross Hospital
Athens, Greece